Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Blood - United States
doi 10.1182/blood-2018-99-113840
Full Text
Open PDFAbstract
Available in full text
Date
November 29, 2018
Authors
Publisher
American Society of Hematology